Rhythm Pharmaceuticals (RYTM) Aandelenoverzicht
Rhythm Pharmaceuticals, Inc., een biofarmaceutisch bedrijf in een commerciële fase, richt zich op de zeldzame neuro-endocriene ziekten in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor RYTM uit onze risicocontroles.
RYTM Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rhythm Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$110.41 |
| 52 Week Hoogtepunt | US$122.20 |
| 52 Week Laag | US$64.65 |
| Bèta | 1.92 |
| 1 maand verandering | 25.65% |
| 3 maanden verandering | 27.95% |
| 1 Jaar Verandering | 64.99% |
| 3 jaar verandering | 589.63% |
| 5 jaar verandering | 462.74% |
| Verandering sinds IPO | 268.03% |
Recent nieuws en updates
Narratiefupdate • Jun 18
RYTM: PWS Phase 2 Progress Will Drive Next Phase Of Upside
Analysts have nudged their average price target on Rhythm Pharmaceuticals stock higher by about $1 to roughly $139, citing updated models that factor in recently reported interim Phase 2 data for setmelanotide in PWS, as well as a series of upward target revisions across the Street. Analyst Commentary Street research around Rhythm Pharmaceuticals centers on how the new Phase 2 setmelanotide data in PWS could affect valuation, execution risk, and the long term growth opportunity.Narratiefupdate • Jun 03
RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside
Narrative Update The updated analyst price target framework for Rhythm Pharmaceuticals reflects a modest fair value move to $138.20, with analysts pointing to adjusted revenue growth expectations, higher projected profit margins, and a lower future P/E assumption after recent EMANATE trial readouts and reassessments of setmelanotide opportunities. Analyst Commentary Recent research updates on Rhythm Pharmaceuticals reflect a mix of optimism around near term commercial execution and concern around the implications of the EMANATE Phase 3 miss for longer term rare obesity opportunities.Recent updates
Narratiefupdate • Jun 18
RYTM: PWS Phase 2 Progress Will Drive Next Phase Of Upside
Analysts have nudged their average price target on Rhythm Pharmaceuticals stock higher by about $1 to roughly $139, citing updated models that factor in recently reported interim Phase 2 data for setmelanotide in PWS, as well as a series of upward target revisions across the Street. Analyst Commentary Street research around Rhythm Pharmaceuticals centers on how the new Phase 2 setmelanotide data in PWS could affect valuation, execution risk, and the long term growth opportunity.Narratiefupdate • Jun 03
RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside
Narrative Update The updated analyst price target framework for Rhythm Pharmaceuticals reflects a modest fair value move to $138.20, with analysts pointing to adjusted revenue growth expectations, higher projected profit margins, and a lower future P/E assumption after recent EMANATE trial readouts and reassessments of setmelanotide opportunities. Analyst Commentary Recent research updates on Rhythm Pharmaceuticals reflect a mix of optimism around near term commercial execution and concern around the implications of the EMANATE Phase 3 miss for longer term rare obesity opportunities.Seeking Alpha • Jun 03
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine
Summary Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE’s recent FDA and EU approvals for acquired hypothalamic obesity unlock a significant, underserved market with rapid early uptake and global expansion potential. RYTM’s premium valuation is justified by rapid revenue growth, multiple approved indications, global infrastructure, and a robust pipeline targeting rare neuroendocrine obesity. Key near-term catalysts include U.S. launch execution, Japanese regulatory decision, pivotal oral bivamelagon trial, and pipeline progress in congenital HO and PWS. Read the full article on Seeking AlphaNarratiefupdate • May 04
RYTM: Hypothalamic Obesity Expansion Will Drive Next Phase Of Upside
Rhythm Pharmaceuticals' consolidated analyst price target has been adjusted slightly higher by a few dollars to $137.67, as analysts update their models around recent EMANATE trial outcomes, hypothalamic obesity launch expectations, and evolving views on next generation MC4R agonist opportunities. Analyst Commentary Recent research updates show a mix of optimism and caution around Rhythm Pharmaceuticals, with several firms adjusting price targets both higher and lower as they factor in EMANATE outcomes, hypothalamic obesity indications, and next generation MC4R agonist programs.Narratiefupdate • Apr 19
RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside
Analysts have nudged their blended price target for Rhythm Pharmaceuticals higher by $0.40 to $137.67, reflecting updated assumptions around revenue growth, profitability, discount rates, and future P/E multiples following recent research updates on Phase 3 trial outcomes and the commercial outlook for Imcivree and hypothalamic obesity. Analyst Commentary Recent research updates present a mixed but generally constructive picture, with several firms adjusting price targets following the EMANATE trial results and evolving expectations for Imcivree and hypothalamic obesity.Narratiefupdate • Apr 04
RYTM: Hypothalamic Obesity Expansion Will Drive Next Upside Phase
Rhythm Pharmaceuticals' fair value estimate has moved higher to $137.27 from $135.53, as analysts factor in recent price target revisions that balance EMANATE trial setbacks with continued focus on Imcivree commercial execution and next generation MC4R agonists. Analyst Commentary Street research around Rhythm Pharmaceuticals has shifted meaningfully following the EMANATE readout, with price targets adjusted both higher and lower as analysts weigh clinical risk against the commercial rollout of Imcivree and the potential of next generation MC4R agonists.Narratiefupdate • Mar 20
RYTM: Hypothalamic Obesity Approval And Launch Preparations Will Drive Next Upside Phase
The updated analyst model trims the blended price target for Rhythm Pharmaceuticals by about $4 to $135.53 as analysts factor in slightly lower revenue growth and margin assumptions, along with a higher projected future P/E multiple following recent EMANATE trial results and ongoing focus on Imcivree and hypothalamic obesity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals reflects a mixed but engaged view, with several firms adjusting price targets after EMANATE and other trial updates, as well as ongoing focus on Imcivree and hypothalamic obesity.Narratiefupdate • Mar 06
RYTM: Hypothalamic Obesity Launch And Upcoming Data Readouts Will Drive Next Upside Phase
Analysts trimmed their blended price target for Rhythm Pharmaceuticals by a few dollars, reflecting slightly more conservative long-term revenue and margin assumptions, even as they continue to highlight the potential of IMCIVREE and the hypothalamic obesity opportunity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals shows a mix of enthusiasm about the IMCIVREE franchise and the hypothalamic obesity opportunity, along with some recalibration of long-term expectations that feeds into updated price targets.Narratiefupdate • Feb 18
RYTM: Stable Franchise Trends Will Support Next Phase Of Upside
Analysts have lifted their price target on Rhythm Pharmaceuticals to $145 from $140, citing slightly stronger than expected preannounced Q4 Imcivree revenue of about $57M and what they see as stable growth trends for the existing franchise. Analyst Commentary Recent commentary centers on how the preannounced Q4 Imcivree revenue of about US$57M feeds into expectations for Rhythm Pharmaceuticals' execution and valuation.Narratiefupdate • Feb 04
RYTM: March Review Decision Will Drive Next Phase Of Upside
Analysts lifted their price target on Rhythm Pharmaceuticals to US$145 from US$140, citing Q4 Imcivree revenues of about US$57 million coming in slightly ahead of expectations and their view that growth in the existing franchise remains stable. Analyst Commentary Recent commentary around Rhythm Pharmaceuticals focuses on how the latest Imcivree revenue update might influence expectations for growth, execution, and valuation.Narratiefupdate • Jan 21
RYTM: March Hypothalamic Obesity Decision Will Drive Next Phase Of Upside
Narrative Update Overview Analysts have inched their fair value estimate for Rhythm Pharmaceuticals higher to about $140 from $139, reflecting slightly higher Street price targets and expectations for steady Imcivree demand after a Q4 revenue preannouncement of roughly $57 million. The update also takes into account more cautious views on how much near term upside is left around upcoming label and trial milestones.Narratiefupdate • Jan 06
RYTM: March Obesity Decision And Prader Willi Data Will Shape Upside
Analysts have nudged their fair value estimate for Rhythm Pharmaceuticals higher to about US$139 per share from roughly US$138, reflecting recent price target increases from several firms, along with views that upcoming label expansion and clinical readouts are already largely reflected in the current share price. Analyst Commentary Recent Street research on Rhythm Pharmaceuticals shows a mix of enthusiasm around the commercial trajectory and upcoming label events, alongside some caution on how much of that story is already reflected in the share price.Narratiefupdate • Dec 21
RYTM: March FDA Obesity Decision Will Drive Next Phase Of Upside
Analysts have modestly lifted their fair value estimate for Rhythm Pharmaceuticals to approximately $138 from about $127, reflecting slightly higher long term revenue growth expectations and confidence in upcoming hypothalamic obesity label expansion, despite a recent downgrade on valuation concerns. Analyst Commentary Bullish analysts highlight that Rhythm's strong clinical execution in hypothalamic obesity and Bardet Biedl syndrome, along with robust year to date share performance, support a higher long term revenue trajectory and justify incremental price target increases.Narratiefupdate • Dec 07
RYTM: March FDA Obesity Decision Will Drive Next Phase Of Share Upside
Analysts have edged their average price target for Rhythm Pharmaceuticals slightly higher to about $127 from roughly $126, reflecting confidence that strong Imcivree and bivamelagon data, along with anticipated hypothalamic obesity label expansion, can support continued growth. However, recent gains and a limited near term catalyst slate are tempering enthusiasm.Narratiefupdate • Nov 23
RYTM: December FDA Decision Will Drive Next Phase Of Share Upside
Rhythm Pharmaceuticals' analyst price target increased from $121.43 to $126.31, as analysts cite ongoing clinical progress and upcoming regulatory milestones that support further upside for the company’s shares. Analyst Commentary Analysts have recently weighed in on Rhythm Pharmaceuticals, offering both optimistic and cautionary perspectives based on the company's performance, upcoming catalysts, and valuation.Analyseartikel • Nov 07
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
It's been a sad week for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ), who've watched their investment drop 12% to...Narratiefupdate • Nov 05
RYTM: Upcoming FDA Decision Will Drive Next Phase of Upside Momentum
Analysts have raised their price target for Rhythm Pharmaceuticals from $117.57 to $121.43 per share, citing improved profit margin projections and increased optimism about upcoming label expansions for setmelanotide. Analyst Commentary Recent updates from Street research provide a balanced view on Rhythm Pharmaceuticals, with both bullish and bearish perspectives influencing the company's outlook and valuation.Narratiefupdate • Oct 22
Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics
The analyst price target for Rhythm Pharmaceuticals was revised upward by $7 to reflect increased optimism from analysts about the company's potential label expansion and expected regulatory progress for setmelanotide in hypothalamic obesity. Analyst Commentary Recent updates from Street research indicate a positive reassessment of Rhythm Pharmaceuticals' prospects, particularly surrounding potential regulatory approval and expanding commercial opportunities for setmelanotide in hypothalamic obesity.Narratiefupdate • Oct 08
Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
Rhythm Pharmaceuticals' analyst price target has increased from $114.86 to $118.36, as analysts cite encouraging clinical data and optimism about setmelanotide's approval prospects in hypothalamic obesity. These factors are driving the revised valuation.Narratiefupdate • Sep 24
Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
The consensus price target for Rhythm Pharmaceuticals was raised to $114.86 as bullish analyst sentiment strengthened on strong Phase 2 obesity trial results, robust Imcivree sales, and optimistic expectations for regulatory milestones and long-term franchise durability. Analyst Commentary Bullish analysts highlight strong Phase 2 trial results for bivamelagon in hypothalamic obesity, demonstrating significant placebo-adjusted BMI reduction at multiple doses and exceeding expectations for efficacy over 14 weeks.Narratiefupdate • Aug 07
Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
A lower future P/E indicates improved earnings expectations, while a higher discount rate suggests increased perceived risk, yet analysts have still raised Rhythm Pharmaceuticals’ fair value to $110.71 per share. What's in the News Rhythm Pharmaceuticals presented new clinical data on bivamelagon (oral MC4R agonist) and setmelanotide (lead asset) in patients with acquired hypothalamic obesity at ENDO 2025; setmelanotide remains FDA approved for syndromic monogenic obesity due to defined genetic deficiencies.Analyseartikel • Jul 10
Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%
Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shares have continued their recent momentum with a 33% gain in the last...Nieuw narratief • May 26
Label Expansion And Global Healthcare Will Widen Future Market Opportunities
Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.Seeking Alpha • Apr 08
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Summary Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmelanotide to the U.S. and EU, for the treatment of patients with acquired hypothalamic obesity, expected in Q3 of 2025. Company pushing forward with oral MC4R-specific agonist to treat patients with acquired hypothalamic obesity known as bivamelagon; Data from a phase 1/2 study, using bivamelagon for the treatment of patients with acquired hypothalamic obesity, expected in 2nd half of 2025. Read the full article on Seeking AlphaSeeking Alpha • Feb 25
Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Summary Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhythm's robust clinical progress and strategic positioning in the rare genetic obesity market. Rating justification is based on solid revenues, innovative product pipeline, and potential market expansion. Conclusion emphasizes Rhythm's growth potential and recommends it as a compelling speculative investment opportunity. Read the full article on Seeking AlphaSeeking Alpha • Dec 06
Rhythm Pharmaceuticals: A Key Year Ahead
Summary Rhythm Pharmaceuticals, Inc.'s main asset, imcivree, targets rare genetic obesity disorders; key milestones in 2025 could significantly impact the stock. Positive Phase 3 data and expanded indications for imcivree, including Hypothalamic Obesity, are crucial for future growth. Analysts are optimistic, with multiple Buy ratings and price targets between $65-$80; however, insiders have sold some shares recently. An updated analysis around Rhythm Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Sep 22
Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Summary IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. Rhythm is also exploring IMCIVREE for hypothalamic obesity in a phase 3 study, with data expected in the 1st half of 2025. Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months. RM-718 and LB54640 are two other drugs being developed to treat patients with hypothalamic obesity; Both of which are able to achieve function without hyperpigmentation. Read the full article on Seeking AlphaSeeking Alpha • Aug 29
Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Summary Rhythm Pharmaceuticals' Q2 revenue rose to $29.1 million, driven by global sales of Imcivree, its treatment for rare genetic obesity disorders. The company's cash and investments totaled $319 million by June 30, 2024, ensuring a cash runway into 2026, according to Rhythm's projections. Imcivree is currently undergoing a Phase 3 trial for hypothalamic obesity, with results expected in 1H 2025, crucial for its potential blockbuster status. RYTM stock is a speculative "buy" based on the potential of Imcivree in treating hypothalamic obesity, though there are significant risks if the trial fails. Read the full article on Seeking AlphaSeeking Alpha • Jun 12
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Summary Rhythm Pharmaceuticals' stock has appreciated 68% since the last sell recommendation, outperforming market returns. Imcivree shows promising Phase 2 results in treating hypothalamic obesity, potentially doubling its market if its Phase 3 trial proves successful. The company's financial health appears stable, with a sufficient cash runway extended by recent funding. The Phase 3 trial for Imcivree in heterozygous mutations aims to broaden the addressable population to exceed 50,000. I now hold a more balanced view of RYTM stock, acknowledging its strategic expansions but cautious of its high valuation and ongoing risks. Read the full article on Seeking AlphaSeeking Alpha • Feb 23
Rhythm Pharmaceuticals: Action Too Specific
Summary Rhythm Pharmaceuticals focuses on treating obesity caused by genetic mutations, but the market size for these mutations is too small to justify the company's valuation. Novo Nordisk's Ozempic also targets the same patient groups, making Rhythm's product less appealing. IMCIVREE, Rhythm's main product, shows good results in clinical trials, but again the action is too specific. Outstanding dilution from options too down the line. Not for us. Read the full article on Seeking AlphaRendement voor aandeelhouders
| RYTM | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 2.7% | 3.7% | 1.6% |
| 1Y | 65.0% | 37.9% | 21.1% |
Rendement versus industrie: RYTM overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 37.9 % opleverde.
Rendement versus markt: RYTM overtrof de US markt, die het afgelopen jaar een rendement opleverde van 21.1 %.
Prijsvolatiliteit
| RYTM volatility | |
|---|---|
| RYTM Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: RYTM heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van RYTM is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2008 | 414 | David Meeker | rhythmtx.com |
Rhythm Pharmaceuticals, Inc., een biofarmaceutisch bedrijf in commerciële fase, richt zich op zeldzame neuro-endocriene ziekten in de Verenigde Staten en internationaal. De belangrijkste productkandidaat van het bedrijf is IMCIVREE (setmelanotide), een zeldzame melanocortine-4 receptor voor de behandeling van pro-opiomelanocortine (POMC), proproteïne convertase subtilisine/kexine type 1, leptinereceptor (LEPR) deficiëntie obesitas, Bardet-Biedl en Alström syndroom, Prader-Willi syndroom, en hypothalamus obesitas. Het is in Fase 3 klinische studies voor de behandeling van verworven hypothalamische obesitas, congenitale hypothalamische obesitas, pro-opiomelanocortine (POMC) en LEPR deficiëntie obesitas, SRC1 deficiëntie obesitas, en SH2B1 deficiëntie obesitas; en in Fase 2 klinische studies voor de behandeling van Prader-Willi syndroom en MC4R deficiëntie.
Rhythm Pharmaceuticals, Inc. Samenvatting
| RYTM fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$7.61b |
| Inkomsten(TTM) | -US$207.84m |
| Inkomsten(TTM) | US$217.17m |
34.8x
P/S-verhouding-36.4x
Koers/WinstverhoudingIs RYTM overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| RYTM resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$217.17m |
| Kosten van inkomsten | US$23.00m |
| Brutowinst | US$194.16m |
| Overige uitgaven | US$402.00m |
| Inkomsten | -US$207.84m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.03 |
| Brutomarge | 89.41% |
| Nettowinstmarge | -95.71% |
| Schuld/Eigen Vermogen Verhouding | 45.6% |
Hoe presteerde RYTM op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/01 20:30 |
| Aandelenkoers aan het einde van de dag | 2026/07/01 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Rhythm Pharmaceuticals, Inc. wordt gevolgd door 25 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Samantha Lynn Semenkow | Citigroup Inc |